

LISTING OF CLAIMS

1.-68. (Cancelled)

~~69.~~¹ (Previously presented) A method for limiting the mitogenic activity of proliferating epithelial cells in a mammal in need thereof, comprising administering to the mammal a composition comprising an isolated morphogen dispersed in a biocompatible carrier so as to contact said morphogen with said epithelial cells, wherein said morphogen:

- (i) has at least 70% homology with the C-terminal seven-cysteine skeleton of human OP-1, residues 38-139 of SEQ ID NO: 5;
- (ii) is not TGF β 2; and
- (iii) is capable of inhibiting lesion formation in an *in vivo* oral mucositis assay, so as to thereby limit the mitogenic activity of said cells in said mammal.

~~70.~~² (Previously presented) The method of claim ~~69~~¹, wherein said epithelial cells are epidermal skin cells.

~~71.~~³ (Previously presented) The method of claim ~~70~~², wherein proliferation of said cells is associated with psoriasis.

~~72.~~⁴ (Previously presented) A method for inhibiting scar tissue formation at a site of tissue damage in a mammal, comprising administering to the mammal a composition comprising an isolated morphogen dispersed in a biocompatible carrier so as to contact said morphogen with cells at a site of tissue damage in the mammal, wherein said morphogen:

- (i) has at least 70% homology with the C-terminal seven-cysteine skeleton of human OP-1, residues 38-139 of SEQ ID NO: 5;
- (ii) is not TGF β 2; and
- (iii) is capable of inhibiting lesion formation in an *in vivo* oral mucositis assay, so as to thereby inhibit scar tissue formation at a site of tissue damage in said mammal.

73. (Cancelled)